Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report)'s stock price was down 4.7% on Monday . The stock traded as low as $11.11 and last traded at $10.96. 29,593 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 293,406 shares. The stock had previously closed at $11.50.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on TYRA. UBS Group started coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $30.50.
Get Our Latest Stock Analysis on TYRA
Tyra Biosciences Price Performance
The firm has a market cap of $540.95 million, a PE ratio of -6.64 and a beta of 1.09. The business has a 50-day moving average price of $13.14 and a two-hundred day moving average price of $16.83.
Insider Buying and Selling
In other news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction on Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares of the company's stock, valued at $6,107,857.60. This represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders have sold 21,998 shares of company stock valued at $344,818. Insiders own 15.40% of the company's stock.
Hedge Funds Weigh In On Tyra Biosciences
A number of institutional investors have recently added to or reduced their stakes in TYRA. RA Capital Management L.P. boosted its holdings in shares of Tyra Biosciences by 2.1% in the 4th quarter. RA Capital Management L.P. now owns 10,637,290 shares of the company's stock valued at $147,858,000 after buying an additional 220,681 shares during the period. Alta Partners Management Company L.P. acquired a new position in shares of Tyra Biosciences in the 4th quarter worth $56,716,000. FMR LLC boosted its stake in Tyra Biosciences by 0.8% in the 3rd quarter. FMR LLC now owns 3,372,850 shares of the company's stock worth $79,296,000 after purchasing an additional 26,187 shares during the period. Boxer Capital Management LLC acquired a new position in shares of Tyra Biosciences in the 4th quarter valued at about $28,185,000. Finally, Janus Henderson Group PLC increased its position in Tyra Biosciences by 63.6% in the 4th quarter. Janus Henderson Group PLC now owns 1,746,320 shares of the company's stock worth $24,291,000 after purchasing an additional 679,124 shares during the last quarter. Institutional investors and hedge funds own 84.14% of the company's stock.
Tyra Biosciences Company Profile
(
Get Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
Read More
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
